The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
New progestagens for contraceptive use
Abstract
The progestins have different pharmacologic properties depending upon the parent molecule, usually testosterone or progesterone (P), from which they are derived. Very small structural changes in the parent molecule may induce considerable differences in the activity of the derivative. In hormonal contraceptives, progestins represent the major agent designed for suppressing ovulation and are used in combination with estrogen (E) usually ethinyl-estradiol (EE). The development of new generations of progestins with improved selectivity profiles has been a great challenge. Steroidal and nonsteroidal progesterone receptor (PR) agonists have been synthesized as well, although the latter are still in a very early stage of development. Several new progestins, have been synthesized in the last two decades. These include dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc) and trimegestone (TMG). These new progestins have been designed to have no androgenic or estrogenic actions and to be closer in activity to the physiological hormone P. DRSP differs from the classic progestins as it is derived from spirolactone. It is essentially an antimineralocorticoid steroid with no androgenic effect but a partial antiandrogenic effect. The antiovulatory potency of the different progestins varies. TMG and NES are the most potent progestins synthesized to date, followed by two of the older progestins, keto-desogestrel (keto-DSG) and levonorgestrel (LNG). The new molecules TMG, DRSP and DNG also have antiandrogenic activity. Striking differences exist regarding the side effects among the progestins and the combination with EE leads to other reactions related to the E itself and whether the associated progestin counterbalances, more or less, the estrogenic action. The 19-norprogesterone molecules and the new molecules DRSP and DNG are not androgenic and, therefore, have no negative effect on the lipid profile. Given their pharmacological properties, it is likely that the new progestins may have neutral effects on metabolic or vascular risks. However, this hypothesis must be confirmed in large clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Classification and pharmacology of progestins
Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R., Schweppe, K. W., & Thijssen, J. H. H. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.014 · Cited by 745
Oral Contraceptives and the Risk of Breast Cancer
Marchbanks, P. A., McDonald, J. A., Wilson, H. G., Folger, S. G., Mandel, M. G., Daling, J. R., Bernstein, L., Malone, K. E., Ursin, G., Strom, B. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013202 · Cited by 532
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
Kemmeren, J. M., Algra, A., & Grobbee, D. E. (2001) · BMJ · doi:10.1136/bmj.323.7305.131 · Cited by 455
Oral contraceptives and the risk of breast cancer*
(2003) · Obstetrics & Gynecology · doi:10.1097/00006250-200304000-00031 · Cited by 431
Fournier, A., Berrino, F., Riboli, E., Avenel, V., & Clavel‐Chapelon, F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20710 · Cited by 403
Mellick, R. S., Mahler, R. F., & Hughes, B. P. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92145-1 · Cited by 390
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Krattenmacher, R. (2000) · Contraception · doi:10.1016/s0010-7824(00)00133-5 · Cited by 376
Giangrande, P. H., & McDonnell, D. P. (1999) · PubMed · Cited by 339
Oelkers, W. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.6.1816 · Cited by 246
Fuhrmann, U., Krattenmacher, R., Slater, E. P., & Fritzemeier, K.-H. (1996) · Contraception · doi:10.1016/s0010-7824(96)00195-3 · Cited by 197
Wynn, V., Godsland, I., Niththyananthan, R., Adams, P. W., Melrose, J., Oakley, N. W., & Seed, M. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92949-0 · Cited by 196
Nestorone®: a progestin with a unique pharmacological profile
Kumar, N. (2000) · Steroids · doi:10.1016/s0039-128x(00)00119-7 · Cited by 184
Odlind, V., Milsom, I., Persson, I. R., & Victor, A. (2002) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1034/j.1600-0412.2002.810603.x · Cited by 183
Musgrove, E. A., Lee, C. S., & Sutherland, R. L. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5032 · Cited by 175
Comparative Pharmacology of Newer Progestogens
Kuhl, H. (1996) · Drugs · doi:10.2165/00003495-199651020-00002 · Cited by 171
Liu, Z., Auboeuf, D., Wong, J., Chen, J. D., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122225699 · Cited by 159
Conception and pharmacodynamic profile of drospirenone
Elger, W. A. G., Beier, S., Pollow, K., Garfield, R. E., Shi, S. Q., & Hillisch, A. (2003) · Steroids · doi:10.1016/j.steroids.2003.08.008 · Cited by 142
Progestogen-only contraception in women at high risk of venous thromboembolism
Conard, J., Plu‐Bureau, G., Bahi, N., Horellou, M., Pelissier, C., & Thalabard, J. (2004) · Contraception · doi:10.1016/j.contraception.2004.07.009 · Cited by 137
Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception
Stanczyk, F. Z. (2002) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1020072325818 · Cited by 122
Dietel, M., Lewis, M. A., & Shapiro, S. (2005) · Human Reproduction · doi:10.1093/humrep/dei043 · Cited by 120
Oelkers, W., BERGER, V., Bolik, A., Bähr, V., Hazard, B., Beier, S., Elger, W. A. G., & HEITHECKER, A. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-4-837 · Cited by 104
Effects of progestogens on haemostasis
Kühl, H. (1996) · Maturitas · doi:10.1016/0378-5122(96)00994-2 · Cited by 103
Sitruk-Ware, R. L. (2004) · Drugs & Aging · doi:10.2165/00002512-200421130-00004 · Cited by 102
Self-citationComparison of hepatic impact of oral and vaginal administration of ethinyl estradiol
Goebelsmann, U., Mashchak, C. A., & Mishell, D. R. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90664-7 · Cited by 99
Nestorone®: clinical applications for contraception and HRT
Sitruk-Ware, R. L., Small, M., Kumar, N., Tsong, Y. Y., Sundaram, K., & Jackanicz, T. M. (2003) · Steroids · doi:10.1016/s0039-128x(03)00140-5 · Cited by 90
Self-citationEffect of four oral contraceptives on hemostatic parameters
Wiegratz, I., Lee, J. H., Kutschera, E., Winkler, U. H., & Kühl, H. (2004) · Contraception · doi:10.1016/j.contraception.2004.03.004 · Cited by 88
Schneider, H. P. G. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1290.033 · Cited by 87
Foster, R. H., & Wilde, M. I. (1998) · Drugs · doi:10.2165/00003495-199856050-00007 · Cited by 87
The pharmacological profile of a novel norpregnane progestin (trimegestone)
Philibert, D., Bouchoux, F., Degryse, M., Lecaque, D., Petit, F., & Gaillard, M. (1999) · Gynecological Endocrinology · doi:10.3109/09513599909167574 · Cited by 78
Farley, T. (1999) · Human Reproduction Update · doi:10.1093/humupd/5.6.721 · Cited by 77
The preclinical biology of a new potent and selective progestin: trimegestone
Winneker, R. C., Bitran, D., & Zhang, Z. (2003) · Steroids · doi:10.1016/s0039-128x(03)00142-9 · Cited by 71
Role of progestins in contraception
Erkkola, R., & Landgren, B. (2005) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/j.0001-6349.2005.00759.x · Cited by 70
Conner, P., Söderqvist, G., Skoog, L. K., Gräser, T., Walter, F., Tani, E. M., Carlström, K., & von Schoultz, B. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1022987618445 · Cited by 68
Contraceptive vaginal rings releasing Nestorone® and ethinylestradiol: a 1-year dose-finding trial
Sivin, I., Mishell, D. R., Alvarez, F., Brache, V., Elomaa, K., Lähteenmäki, P., Massai, R., Miranda, P., Croxatto, H. B., Dean, C., et al. (2005) · Contraception · doi:10.1016/j.contraception.2004.08.010 · Cited by 67
In vitro characterization of trimegestone: a new potent and selective progestin
Zhang, Z., Lundeen, S. G., Zhu, Y., Carver, J. M., & Winneker, R. C. (2000) · Steroids · doi:10.1016/s0039-128x(00)00120-3 · Cited by 63
One year contraception with a single subdermal implant containing nomegestrol acetate (uniplant)
Coutinho, E. M. (1993) · Contraception · doi:10.1016/0010-7824(93)90112-k · Cited by 60
Pollow, K., Juchem, M., Elger, W. A. G., Jacobi, N., Hoffmann, G. M., & Möbus, V. J. (1992) · Contraception · doi:10.1016/0010-7824(92)90121-9 · Cited by 57
The contraceptive vaginal ring (NuvaRing®) and hemostasis: a comparative study
Magnúsdóttir, E. M., Bjarnadóttir, R. I., Onundarson, P. T., Guðmundsdóttir, B. R., Geirsson, R. T., Magnusdóttir, S. D., & Dieben, T. O. M. (2004) · Contraception · doi:10.1016/j.contraception.2003.12.010 · Cited by 52
Effect of dienogest-containing oral contraceptives on lipid metabolism
Wiegratz, I., Lee, J. H., Kutschera, E., Bauer, H., Hayn, C., Moore, C., Mellinger, U., Winkler, U. H., Gross, W., & Kühl, H. (2002) · Contraception · doi:10.1016/s0010-7824(01)00310-9 · Cited by 49
Catherino, W. H., & Jordan, V. C. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00171-u · Cited by 49
Bazin, B., Thévenot, R., Cd, B., & Pâris, J. (1987) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1987.tb02322.x · Cited by 48
Lundeen, S. G., Zhang, Z., Zhu, Y., et al. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00091-7 · Cited by 46
Ovarian function during use of vaginal rings delivering three different doses of Nestorone®
Brache, V., Mishell, D. R., Lähteenmäki, P., Alvarez, F., Elomaa, K., Jackanicz, T. M., & Faúndes, A. (2001) · Contraception · doi:10.1016/s0010-7824(01)00199-8 · Cited by 46
The in Vivo Glucocorticoid and Antiglucocorticoid Actions of Medroxyprogesterone Acetate
Guthrie, G. P., & John, W. J. (1980) · Endocrinology · doi:10.1210/endo-107-5-1393 · Cited by 44
Nelson, A. (1996) · PubMed · Cited by 42
Safety of a New Oral Contraceptive Containing Drospirenone
Heinemann, L. A. J., & Dinger, J. (2004) · Drug Safety · doi:10.2165/00002018-200427130-00003 · Cited by 38
Suparto, I. H., Williams, J. K., Cline, J. M., Anthony, M. S., & Fox, J. L. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.237 · Cited by 29
Alkhalaf, M., El‐Mowafy, A. M., & Karam, S. M. (2002) · European Journal of Cancer Prevention · doi:10.1097/00008469-200210000-00011 · Cited by 28
Exogenous progestagens and the human breast
Sitruk-Ware, R. L., & Plu‐Bureau, G. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.06.007 · Cited by 26
Self-citationPharmacology of estradiol valerate/dienogest.
Teichmann, A. T. (2003) · PubMed · Cited by 24
Devoto, L., Kohen, P., Barnhart, K. T., Alba, F., Pommer, R., Retamales, I., & Coutinho, E. M. (1997) · Human Reproduction · doi:10.1093/humrep/12.4.708 · Cited by 17
Effects of a progestogen on normal human breast epithelial cell apoptosis in vitro and in vivo
Desreux, J., Kebers, F., Noël, A., et al. (2003) · The Breast · doi:10.1016/s0960-9776(03)00003-1 · Cited by 13
Research works printed but not linked: 17
- Bouali, 2001, Gynecol Endocrinol, 15, 48, 10.1080/gye.15.1.48.55 · doi:10.1080/gye.15.1.48.55
- Catherino, 1993, Br J Cancer, 67, 945, 10.1038/bjc.1993.175 · doi:10.1038/bjc.1993.175
- Duc, 1995, Arzneimittelforschung, 45, 70
- Erkkola, 2005, Acta Obstet Gynecol Scand, 84, 207, 10.1111/j.0001-6349.2005.00759.x · doi:10.1111/j.0001-6349.2005.00759.x
- Fotherby, 1990, Contraception, 41, 533, 10.1016/0010-7824(90)90062-Z · doi:10.1016/0010-7824(90)90062-z
- Giangrande, 1999, Recent Prog Horm Res, 54, 291
- Grubb, 2003, Steroids, 68, 921, 10.1016/j.steroids.2003.09.001 · doi:10.1016/j.steroids.2003.09.001
- Maillard-Salin, 2000, Int J Pharm, 199, 29, 10.1016/S0378-5173(00)00357-4 · doi:10.1016/s0378-5173(00)00357-4
- Massai, 2001, Contraception, 64, 369, 10.1016/S0010-7824(01)00259-1 · doi:10.1016/s0010-7824(01)00259-1
- Musgrove, 1991, Mol Cell Biol, 11, 5032
- Nelson, 1996, J Reprod Med, 41, 391
- Noe, 1993, Contraception, 48, 548, 10.1016/0010-7824(93)90117-P · doi:10.1016/0010-7824(93)90117-p
- Odlind, 2002, Acta Obstet Gynecol Scand, 81, 482
- Oelkers, 1995, J Clin Endocrinol Metab, 80, 1816
- Oettel, 2001, Drugs Today, 37, 3
- Paris, 1983, Arzneimittelforschung, 33, 710
- Teichmann, 2003, Climacteric, 6, 17
Cited by
Combined oral contraceptives: venous thrombosis
de Bastos, M., Stegeman, B. H., Rosendaal, F. R., Van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010813.pub2 · Cited by 399
Sex hormones, appetite and eating behaviour in women
Hirschberg, A. L. (2012) · Maturitas · doi:10.1016/j.maturitas.2011.12.016 · Cited by 338
[Ca2+]i signalling in sperm — making the most of what you've got
Publicover, S., Harper, C. V., & Barratt, C. (2007) · Nature Cell Biology · doi:10.1038/ncb0307-235 · Cited by 292
Oral contraceptives containing drospirenone for premenstrual syndrome
Lopez, L. M., Kaptein, A. A., & Helmerhorst, F. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006586.pub4 · Cited by 270
Sitruk-Ware, R., & Nath, A. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.09.004 · Cited by 247
Metadata
- Authors
- Sitruk-Ware, R.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-16
- Volume
- 12
- Issue
- 2
- Pages
- 169-178
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2100560126
- Cited by
- 362
- References
- 54
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.